Janssen R&D Ireland has amended its 2011 agreement with Gilead for the development of a once daily, darunavir-based, single-tablet regimen (STR) for the treatment of HIV. This new STR contains a combination of darunavir (PREZISTA), cobicistat (TYBOST), emtricitabine and tenofovir alafenamide (TAF). Several Phase I and II studies of the new STR have been completed. If approved, this treatment would represent the first protease inhibitor-based STR.   Under this amended agreement, Janssen will ...